GLP1R and diabetes mellitus: Subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is gaining popularity for glycemic control in type 2 diabetes mellitus patients due to its lower risk of hypoglycemia, weight loss benefits, and convenient weekly injection [8].